Standard BioTools Inc. FLB.F Stock
Standard BioTools Inc. Price Chart
Standard BioTools Inc. FLB.F Financial and Trading Overview
Standard BioTools Inc. stock price | 2.68 EUR |
Previous Close | 1.98 EUR |
Open | 1.99 EUR |
Bid | 1.99 EUR x 50000 |
Ask | 2.06 EUR x 50000 |
Day's Range | 1.99 - 1.99 EUR |
52 Week Range | 0.92 - 2.36 EUR |
Volume | 500 EUR |
Avg. Volume | 103 EUR |
Market Cap | 155.99M EUR |
Beta (5Y Monthly) | 1.534859 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.88 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 12 EUR |
FLB.F Valuation Measures
Enterprise Value | 418.6M EUR |
Trailing P/E | N/A |
Forward P/E | -2.6891892 |
PEG Ratio (5 yr expected) | 1.05 |
Price/Sales (ttm) | 1.6153799 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 4.335 |
Enterprise Value/EBITDA | -4.3 |
Trading Information
Standard BioTools Inc. Stock Price History
Beta (5Y Monthly) | 1.534859 |
52-Week Change | 18.77% |
S&P500 52-Week Change | 20.43% |
52 Week High | 2.36 EUR |
52 Week Low | 0.92 EUR |
50-Day Moving Average | 1.79 EUR |
200-Day Moving Average | 1.54 EUR |
FLB.F Share Statistics
Avg. Volume (3 month) | 103 EUR |
Avg. Daily Volume (10-Days) | 420 EUR |
Shares Outstanding | 78.38M |
Float | 50.87M |
Short Ratio | N/A |
% Held by Insiders | 2.21% |
% Held by Institutions | 64.69% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -135.30% |
Operating Margin (ttm) | -104.29% |
Gross Margin | 1.06% |
EBITDA Margin | -100.81% |
Management Effectiveness
Return on Assets (ttm) | -19.55% |
Return on Equity (ttm) | -110.62% |
Income Statement
Revenue (ttm) | 96.56M EUR |
Revenue Per Share (ttm) | 1.23 EUR |
Quarterly Revenue Growth (yoy) | -5.20% |
Gross Profit (ttm) | -1447000 EUR |
EBITDA | -97351000 EUR |
Net Income Avi to Common (ttm) | -130653000 EUR |
Diluted EPS (ttm) | -1.53 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 154.54M EUR |
Total Cash Per Share (mrq) | 1.97 EUR |
Total Debt (mrq) | 101.98M EUR |
Total Debt/Equity (mrq) | 47.63 EUR |
Current Ratio (mrq) | 4.452 |
Book Value Per Share (mrq) | -1.235 |
Cash Flow Statement
Operating Cash Flow (ttm) | -82265000 EUR |
Levered Free Cash Flow (ttm) | -44595376 EUR |
Profile of Standard BioTools Inc.
Country | Germany |
State | CA |
City | South San Francisco |
Address | 2 Tower Place |
ZIP | 94080 |
Phone | 650 266 6000 |
Website | https://www.fluidigm.com |
Industry | Diagnostics & Research |
Sector(s) | Healthcare |
Full Time Employees | 523 |
Standard BioTools Inc., together with its subsidiaries, creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Q&A For Standard BioTools Inc. Stock
What is a current FLB.F stock price?
Standard BioTools Inc. FLB.F stock price today per share is 2.68 EUR.
How to purchase Standard BioTools Inc. stock?
You can buy FLB.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Standard BioTools Inc.?
The stock symbol or ticker of Standard BioTools Inc. is FLB.F.
Which industry does the Standard BioTools Inc. company belong to?
The Standard BioTools Inc. industry is Diagnostics & Research.
How many shares does Standard BioTools Inc. have in circulation?
The max supply of Standard BioTools Inc. shares is 382.46M.
What is Standard BioTools Inc. Price to Earnings Ratio (PE Ratio)?
Standard BioTools Inc. PE Ratio is now.
What was Standard BioTools Inc. earnings per share over the trailing 12 months (TTM)?
Standard BioTools Inc. EPS is -0.88 EUR over the trailing 12 months.
Which sector does the Standard BioTools Inc. company belong to?
The Standard BioTools Inc. sector is Healthcare.